Transglutaminase (tTG) IgA and IgG antibodies

Overview

Transglutaminase (tTG) IgA and IgG antibodies are important blood markers used in the diagnosis of celiac disease, an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. Tissue transglutaminase (tTG) is an enzyme responsible for repairing tissue damage in the body. In celiac disease, however, the immune system mistakenly produces anti-tTG antibodies that attack this enzyme, leading to intestinal injury.

Two major antibody classes are used in testing:

1. tTG IgA antibodies – Highly sensitive and considered the gold standard initial screening test for celiac disease.
2. tTG IgG antibodies – Especially useful in cases of IgA deficiency, ensuring diagnosis is not missed.

Both antibodies help detect active disease and monitor treatment, especially when patients follow a gluten-free diet.

Symptoms

The production of Transglutaminase antibodies correlates with the clinical signs of celiac disease and related disorders. Common symptoms include:

1. Gastrointestinal Symptoms:
   1. Abdominal pain and bloating
   2. Chronic diarrhea or constipation
   3. Nausea and vomiting
   4. Poor growth and weight loss in children
2. Extraintestinal Symptoms:
   1. Fatigue and weakness
   2. Skin rashes such as dermatitis herpetiformis
   3. Iron-deficiency anemia
   4. Osteoporosis due to poor calcium absorption
3. Long-term Complications:
   1. Developmental delays in children
   2. Malnutrition-related problems
   3. Increased risk of intestinal damage if untreated

Antibody detection helps identify these symptoms early, guiding proper medical intervention.

Causes

The main cause of elevated tTG IgA and IgG antibodies is celiac disease, where gluten ingestion triggers an abnormal immune response.

1. Pathophysiology:
   1. Deamidation pathway: Transglutaminase modifies gluten peptides by converting glutamine to glutamic acid, enhancing recognition by immune cells.
   2. Transamidation pathway: Transglutaminase forms stable complexes with gliadin peptides, activating B cells to produce anti-tTG autoantibodies.
   3. This immune reaction leads to chronic inflammation and damage to the intestinal mucosa.
2. Other causes of raised antibodies may include:
   1. Dermatitis herpetiformis (skin manifestation of gluten sensitivity)
   2. Rarely, other autoimmune disorders where cross-reactivity occurs

Thus, anti-tTG antibody production is a direct reflection of the body’s abnormal immune response to gluten.

Risk Factors

Several factors increase the likelihood of developing celiac disease and testing positive for Transglutaminase antibodies:

1. Genetic Susceptibility:
   1. Individuals with HLA-DQ2 or HLA-DQ8 alleles are at greater risk.
2. Family History:
   1. Close relatives of celiac patients are more likely to develop the condition.
3. Associated Autoimmune Disorders:
   1. Type 1 diabetes, autoimmune thyroid disease, and other conditions can coexist with celiac disease.
4. IgA Deficiency:
   1. Since Transglutaminase IgA is the first-line test, patients with IgA deficiency require additional IgG-based testing for accurate results.
5. Age and Environmental Triggers:
   1. Early exposure to gluten and certain environmental triggers may influence disease onset.
6. Untreated Gluten Intake:
   1. Continued consumption of gluten in susceptible individuals perpetuates antibody production and intestinal injury.

Recognizing these risk factors enables targeted screening and timely diagnosis.

Prevention

While genetic predisposition cannot be prevented, the complications of celiac disease and abnormal Transglutaminase antibody production can be reduced through proactive steps:

1. Screening and Early Detection:
   1. Routine testing with tTG IgA and, if necessary, tTG IgG helps in early diagnosis of celiac disease.
   2. In suspected IgA deficiency, dual testing with Transglutaminase and deamidated gliadin peptides (DGP) is recommended.
2. Gluten-Free Diet:
   1. The only effective preventive and treatment strategy is a strict lifelong gluten-free diet.
   2. Avoid wheat, rye, and barley-based foods while opting for naturally gluten-free alternatives.
3. Monitoring Treatment:
   1. Declining antibody levels after adopting a gluten-free diet confirm successful management.
   2. Repeat antibody testing helps track recovery and compliance.
4. Patient Education:
   1. Awareness about gluten-containing foods and hidden sources is essential.
   2. Families of diagnosed patients should also undergo screening due to genetic risk.

By combining dietary management with regular monitoring, individuals can significantly reduce symptoms and long-term complications.